Focused On-demand Library for PR domain zinc finger protein 13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H4Q3

UPID:

PRD13_HUMAN

Alternative names:

PR domain-containing protein 13

Alternative UPACC:

Q9H4Q3; Q5TGC1; Q5TGC2

Background:

PR domain zinc finger protein 13, alternatively known as PR domain-containing protein 13, plays a pivotal role in the human body. It is involved in transcriptional regulation and is essential for the differentiation of KISS1-expressing neurons in the hypothalamus. Furthermore, it acts as a critical regulator of GABAergic cell fate in the cerebellum, ensuring normal postnatal development.

Therapeutic significance:

The protein is linked to severe neurological disorders, including cerebellar dysfunction with impaired intellectual development and hypogonadotropic hypogonadism, and pontocerebellar hypoplasia 17. These associations highlight its potential as a target for therapeutic intervention in these debilitating conditions.